D-retro-inverso FOXO4 peptide (experimental senolytic)
FOXO4-DRI
Designed peptide that disrupts FOXO4–p53 interaction, causing of senescent cells in mouse models.
Primary Mechanism of Action
Clinical / Scientific
FOXO4-DRI was engineered to block FOXO4 binding to p53, releasing p53 to trigger preferentially in senescent cells in research papers. Human senolytic therapy is not established.
Pathway Targets
FOXO4–p53 interaction
Scientific explanation
Disruption leading to senescent-cell in models.
Apoptosis
Scientific explanation
p53-dependent cell death programme.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: FOXO4–p53 interaction → Apoptosis
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| FOXO4/p53 | PPI disruption | Senescence biology | Preclinical |
In Plain Language
FOXO4-DRI is a lab peptide meant to unstick two proteins (FOXO4 and p53) so old “zombie” cells can die in mice. It is not an approved human senolytic.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Apoptosis
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.